Crizanlizumab
Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.
| Trade Name | Adakveo |
|---|---|
| Common Name | Crizanlizumab |
| Indication | sickle cell anemia |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
